ARA-290
MODERATE EVIDENCEAlso known as: Cibinetide, Helix B surface peptide
Investigational — completed clinical trials, not approved
Educational Overview
An 11-amino-acid peptide derived from erythropoietin's helix B, engineered to retain tissue-protective signalling without erythropoietic activity.
Research Mechanism
Acts on the innate repair receptor rather than the classical EPO receptor — the design intent being tissue protection without effects on red cell production.
Areas of Study
- Small-fibre neuropathy (clinical trials)
- Tissue-protective signalling
Safety Considerations
Investigational. Completed trials for specific indications but is not approved. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
How do I get pricing?
Request a quote and our team will respond with current pricing and available sizes for your account.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.